×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GERN – geron corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GERN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
04:30 pm
gern
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/18
01:52 pm
gern
Geron Corporation (NASDAQ:GERN) is a favorite amongst institutional investors who own 72% [Yahoo! Finance]
Medium
Report
Geron Corporation (NASDAQ:GERN) is a favorite amongst institutional investors who own 72% [Yahoo! Finance]
12/18
09:13 am
gern
Headlamp Health Appoints Veteran Healthcare Technology Leader as Chief Executive Officer and Board Member [Yahoo! Finance]
Medium
Report
Headlamp Health Appoints Veteran Healthcare Technology Leader as Chief Executive Officer and Board Member [Yahoo! Finance]
12/13
09:29 am
gern
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Low
Report
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
12/13
06:36 am
gern
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
Neutral
Report
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
12/10
09:32 am
gern
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies [Yahoo! Finance]
Low
Report
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies [Yahoo! Finance]
12/10
09:22 am
gern
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis [Yahoo! Finance]
Low
Report
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis [Yahoo! Finance]
12/10
09:00 am
gern
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
Low
Report
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:46 pm
gern
Form SC 13G/A GERON CORP Filed by: RA CAPITAL MANAGEMENT, L.P.
Low
Report
Form SC 13G/A GERON CORP Filed by: RA CAPITAL MANAGEMENT, L.P.
11/14
09:31 am
gern
Form SC 13G/A GERON CORP Filed by: Deep Track Capital, LP
Medium
Report
Form SC 13G/A GERON CORP Filed by: Deep Track Capital, LP
11/14
06:26 am
gern
Form SC 13G GERON CORP Filed by: RTW INVESTMENTS, LP
Medium
Report
Form SC 13G GERON CORP Filed by: RTW INVESTMENTS, LP
11/12
04:06 pm
gern
Form 3 GERON CORP For: Nov 11 Filed by: Eid Joseph
Low
Report
Form 3 GERON CORP For: Nov 11 Filed by: Eid Joseph
11/12
04:05 pm
gern
Form 4 GERON CORP For: Nov 11 Filed by: Eid Joseph
Low
Report
Form 4 GERON CORP For: Nov 11 Filed by: Eid Joseph
11/7
04:06 pm
gern
Form 10-Q GERON CORP For: Sep 30
Low
Report
Form 10-Q GERON CORP For: Sep 30
11/7
07:05 am
gern
Form 8-K GERON CORP For: Nov 01
Medium
Report
Form 8-K GERON CORP For: Nov 01
10/1
04:05 pm
gern
Form 4 GERON CORP For: Sep 30 Filed by: Spiegel Robert J.
Low
Report
Form 4 GERON CORP For: Sep 30 Filed by: Spiegel Robert J.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/30
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
13.6%
3/17 Geron Co. (NASDAQ: GERN) had its price target lowered by analysts at B. Riley from $4.00 to $3.50. They now have a "buy" rating on the stock. 10.5%
3/19 GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm 10.2%
3/20 Geron Co. (NASDAQ: GERN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 8.9%
10/10 Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 7.0%
1/13 Form 4 GERON CORP For: Jan 10 Filed by: O'Farrell Elizabeth G. 6.7%
3/12 Q4/2019 12/31/2019 EPS -0.150 ZacksConsensus -0.200 ActVsEst 0.050 - Beat 6.5%
8/15 Geron Co. (NASDAQ: GERN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 6.1%
8/8 Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 5.8%
3/20 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline 3 Days Away, Investors with Losses Encouraged to Contact Firm 5.8%
3/17 Geron Co. (NASDAQ: GERN) had its price target lowered by analysts at B. Riley from $4.00 to $3.50. They now have a "buy" rating on the stock. 10.5%
3/19 GERN FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Geron Corporation Investors of Class Action and Encourages Investors to Contact the Firm 10.2%
3/20 Geron Co. (NASDAQ: GERN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.25 price target on the stock. 8.9%
10/10 Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 7.0%
1/13 Form 4 GERON CORP For: Jan 10 Filed by: O'Farrell Elizabeth G. 6.7%
3/12 Q4/2019 12/31/2019 EPS -0.150 ZacksConsensus -0.200 ActVsEst 0.050 - Beat 6.5%
8/15 Geron Co. (NASDAQ: GERN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 6.1%
8/8 Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes 5.8%
3/20 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: Application Deadline 3 Days Away, Investors with Losses Encouraged to Contact Firm 5.8%
TOP News Decliners
5/16
Geron Provides Imetelstat Program Update
-9.8%
3/5 Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -9.7%
9/3 Geron Co. (NASDAQ: GERN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -7.6%
3/15 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: 8 Days Remain Until Application Deadline, Investors with Losses Encouraged to Contact Firm -7.3%
6/17 Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress -6.4%
11/15 Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT [Yahoo! Finance News] -5.1%
8/22 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.9%
12/19 Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -4.7%
10/17 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.7%
1/30 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Geron Corporation (GERN) -4.4%
3/5 Geron to Announce Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 -9.7%
9/3 Geron Co. (NASDAQ: GERN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. -7.6%
3/15 HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Geron Corporation (GERN) Investors: 8 Days Remain Until Application Deadline, Investors with Losses Encouraged to Contact Firm -7.3%
6/17 Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress -6.4%
11/15 Edited Transcript of GERN earnings conference call or presentation 7-Nov-19 1:00pm GMT [Yahoo! Finance News] -5.1%
8/22 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.9%
12/19 Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) -4.7%
10/17 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -4.7%
1/30 The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Geron Corporation (GERN) -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: